Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14342885 | 0.77 | NT5E (0.42) | SMN1; SMN2HDAC1NT5ENPSR1POLB | |
| SCHEMBL2531939 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2NPSR1KDM4EALDH1A1MAPT | |
| SCHEMBL16166910 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL2270379 | 0.74 | PIK3CA (0.54) | SMN1; SMN2NPSR1KDM4EALDH1A1MAPT | |
| SCHEMBL2274542 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2NPSR1KDM4EPOLBPIK3CD | |
| SCHEMBL2275660 | 0.72 | PIK3CD (0.53) | SMN1; SMN2KDM4EALDH1A1POLBPIK3CD | |
| SCHEMBL12370236 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL2271401 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL12370256 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2HDAC1NT5EKDM4EALDH1A1 | |
| SCHEMBL2272803 | 0.72 | PIK3CD (0.40) | SMN1; SMN2HDAC1NPSR1PIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011101429-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | SMN1; SMN2 3309/4885HDAC1 2906/4885NT5E 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.